Anlotinib Plus S-1 for Patients with EGFR Mutation-Negative Advanced Squamous Cell Lung Cancer with PS Scores of 2–3 After Progression of Second-Line or Later-Line Treatment

Anlotinib Plus S-1 for Patients with EGFR Mutation-Negative Advanced Squamous Cell Lung Cancer with PS Scores of 2–3 After Progression of Second-Line or Later-Line Treatment

Xiao-Hong Xie,* Fei Wang,* Xin-Qing Lin, Yin-Yin Qin, Zhan-Hong Xie, Jie-Xia Zhang, Ming Ouyang, Cheng-Zhi Zhou State Key Laboratory of Respiratory Disease, National Clinical Research Center of Respiratory Disease, Guangzhou Institute of the Respiratory Health, First Affiliated Hospital of Guangzhou...

Full description

Bibliographic Details
Main Authors: Xie XH, Wang F, Lin XQ, Qin YY, Xie ZH, Zhang JX, Ouyang M, Zhou CZ
Format: Article
Language:English
Published: Dove Medical Press 2020-12-01
Series:Cancer Management and Research
Subjects:
anlotinib
s-1
advanced squamous cell lung cancer
performance status
efficacy
Online Access:https://www.dovepress.com/anlotinib-plus-s-1-for-patients-with-egfr-mutation-negative-advanced-s-peer-reviewed-article-CMAR

Internet

https://www.dovepress.com/anlotinib-plus-s-1-for-patients-with-egfr-mutation-negative-advanced-s-peer-reviewed-article-CMAR

Similar Items